Bristol Myers Squibb application for Zeposia (ozanimod) for the treatment of ulcerative colitis accepted for filing with priority review by U.S. FDA

BMS

1 February 2021 - U.S. Food and Drug Administration assigned an action date of 30 May 2021.

Bristol Myers Squibb today announced that the U.S. FDA has accepted its supplemental new drug application for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis. 

Following the redemption of a priority review voucher with the submission, the FDA assigned a Prescription Drug User Fee Act goal date of 30 May 2021.

Read BMS press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Priority review , Dossier